文献速递妇科

尼拉帕利联合贝伐珠单抗作为晚期卵巢癌一线铂类化疗联合贝伐珠单抗后维持治疗的2期试验:OVARIO最终分析与总生存结果

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
PubMed 文献 · Gynecol Oncol · 2025-07-01

OVARIO是一项2期单臂开放标签试验,评估晚期卵巢癌患者一线铂类化疗联合贝伐珠单抗后使用尼拉帕利联合贝伐珠单抗维持治疗。最终分析中位随访65.7个月,总体人群中位总生存期为61.1个月,安全性无新信号,健康相关生活质量未受负面影响。

要点

  • 总体人群中位总生存期为61.1个月(95%CI 44.9个月-不可评估)。
  • 同源重组缺陷亚组中位总生存期不可评估(95%CI 58.2个月-不可评估)。
  • 安全性无新信号,健康相关生活质量未受负面影响。

核心结论

  • OVARIO试验最终分析显示,总体人群中位总生存期为61.1个月。
  • 安全性特征与尼拉帕利和贝伐珠单抗单药已知安全性一致。

研究设计与样本

  • 2期、单臂、开放标签试验(NCT03326193)。
  • 纳入成人IIIB-IV期上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,需尝试过减瘤手术且一线铂类化疗联合至少3个周期贝伐珠单抗后达到完全缓解、部分缓解或无疾病证据。
  • 主要终点为18个月无进展生存率(按RECIST标准),次要终点包括无进展生存期、总生存期、安全性和健康相关生活质量(采用FOSI评估)。
  • 最终分析数据截止日期为2024年8月12日,可评估患者N=105。

主要发现

  • 中位随访时间为65.7个月。
  • 总体人群中位总生存期为61.1个月(95%CI 44.9个月-不可评估),成熟度52.4%。
  • 同源重组缺陷亚组中位总生存期不可评估(95%CI 58.2个月-不可评估)。
  • 同源重组 proficient 亚组中位总生存期为38.7个月(95%CI 21.9-63.8个月)。
  • 同源重组状态未确定亚组中位总生存期为39.8个月(95%CI 21.7个月-不可评估)。

关键数值与推荐

  • 总体人群中位总生存期为61.1个月(95%CI 44.9个月-不可评估;成熟度52.4%)。
  • 同源重组缺陷亚组中位总生存期不可评估(95%CI 58.2个月-不可评估)。
  • 同源重组 proficient 亚组中位总生存期为38.7个月(95%CI 21.9-63.8个月)。
  • 同源重组状态未确定亚组中位总生存期为39.8个月(95%CI 21.7个月-不可评估)。
  • 73.3%的患者接受了后续抗癌治疗,30.5%接受了后续PARP抑制剂治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report long-term outcomes from the OVARIO trial of niraparib plus bevacizumab maintenance following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer. METHODS: The phase 2, single-arm, open-label trial enrolled adult patients with stage IIIB-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (NCT03326193). Patients were required to have attempted debulking surgery and have a complete or partial response or no evidence of disease following first-line, platinum-based chemotherapy with ≥3 cycles of bevacizumab. The primary endpoint was 18-month progression-free survival (PFS) rate, per RECIST. Secondary endpoints included PFS, overall survival (OS), safety, and health-related quality of life (HRQOL) as assessed by the Functional Assessment of Cancer Therapy-Ovarian Symptoms Index (FOSI). Final analysis cutoff date, August 12, 2024. RESULTS: The median duration of follow-up was 65.7 months. Among evaluable patients (N = 105), PFS results were consistent with the primary analysis. Median OS (95% CI) was 61.1 months (44.9 months-not evaluable [NE]; 52.4% maturity) in the overall population, NE (58.2 months-NE) in the homologous recombination-deficient, 38.7 months (21.9-63.8 months) in the homologous recombination-proficient, and 39.8 months (21.7 months-NE) in the homologous recombination status not determined subgroups. Most patients (73.3%) received subsequent anticancer therapy; 30.5% received subsequent PARP inhibitor therapy. No new safety signals were identified; safety remained consistent with the primary analysis. Per FOSI, HRQOL was not negatively affected. CONCLUSION: In OVARIO, median OS was 61.1 months in the overall population. Safety was consistent with known safety profiles of niraparib and bevacizumab as monotherapies.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hardesty MM, Krivak TC, Wright GS, et al. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025. PMID: 40602355. doi:10.1016/j.ygyno.2025.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。